Shire dodges HAE competition with $5.9B Dyax buyout

Dyax's ($DYAX) Phase III-ready prospect, DX-2930, would have competed directly with Shire's ($SHPG) Cinryze if and when it hit the market. But the Dublin drugmaker found a way to avoid the rivalry: a $5.9 billion buyout of the Massachusetts biotech. The deal will bolster the company's hereditary angioedema (HAE) franchise, which generates 15% of Shire's revenue and about 20% of earnings, Bernstein analyst Ronny Gal said in an investor note. More from FiercePharma

Suggested Articles

Disease awareness campaigns need to go where the patients are, and today that means digital. That's been even more important during the pandemic.

Changing adult healthcare habits is difficult, but GSK's general vaccine awareness campaign begun this summer reports early successes.

Pharma companies have joined the “get out the vote” trend this election by giving time off to vote and encouraging volunteering at the polls.